Business
Baxter supplies intravenous solutions, infusion systems, nutrition products, monitoring equipment and other essential hospital technologies.
Baxter grew revenue and remained free-cash-flow positive, but a large loss and two discontinued businesses made the retained healthcare portfolio difficult to judge.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 5.7%OK
- Profitability — The net loss widened from $649M to $957MWatch
- Cash flow — Free cash flow declined 42.1% to $332M from $573MWatch
- Margins — Operating margin contracted 287 bps to -2.74%Watch
- Accounting — Portfolio simplification with loss and comparability caveatsNote
- Insiders — 0 purchases and 0 salesNote
Where the revenue comes from
Fiscal 2025, as BAXTER INTERNATIONAL INC reports it. History and quarterly detail are in the app.
- Medical Products & Therapies$5.3B
- Healthcare Systems & Technologies$3.1B
- Pharmaceuticals$2.5B
Leadership changes
From BAXTER INTERNATIONAL INC's own filings, the day they're filed.
- Andrew Hider · Chief Executive Officer · departureeff. 2025-10-29
- Peter M. Wilver · Directors · departureeff. 2024-12-31
- Jeffrey A. Craig · Director · appointmenteff. 2024-09-08
Latest filings
- 8-K · Company announcement2026-08-19
- 8-K · Company announcement2026-08-18
- 8-K · Company announcement2026-08-04
- 8-K · Company announcement2026-08-04
- 10-Q · Quarterly report2026-07-30
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about BAXTER INTERNATIONAL INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.